Global Non-Alcoholic Steatohepatitis Treatment Market Analysis: Size, Drivers, Trends, Opportunities, And Strategies
Save up to 30% on The Business Research Company’s comprehensive market research reports for a limited time only!
At What Rate is the Non-Alcoholic Steatohepatitis Treatment Market Predicted to Expand Between 2024 and 2033?
The market size for treatment of non-alcoholic steatohepatitis has seen a dramatic surge in the past few years. The size is forecasted to increase from $1.89 billion in 2023 to $2.62 billion in 2024, marking a compound annual growth rate (CAGR) of 38.7%. Factors contributing to this significant growth in the past include rising cases of nash, better awareness and diagnosis methods, changes in lifestyle and burgeoning obesity conditions, advancements in clinical research, improved healthcare architecture and accessibility, supportive regulatory measures, and clinical trials.
The market for non-alcoholic steatohepatitis treatment is projected to experience a tremendous growth trajectory in the upcoming years, escalating to an amazing $9.89 billion by 2028 with a compound annual growth rate (CAGR) of 39.4%. This expected growth in the forecast period can be ascribed to progress in drug creation, enhanced understanding of the disease, increasing occurrence and risk factors, and a transition to personalized medicine. Key trends predicted for the forecast period encompass a patient-focused approach, technological progression, specialized treatments, regulatory changes, and advancements in research.
Claim Your Free Sample of the Global Non-Alcoholic Steatohepatitis Treatment Market Report Today!
https://www.thebusinessresearchcompany.com/sample.aspx?id=8595&type=smp
What Forces Are Boosting the non-alcoholic steatohepatitis treatment Market’s Growth?
The surge in insulin resistance occurrences has contributed to the expansion of the non-alcoholic steatohepatitis treatment market. Insulin resistance, which leads to high blood sugar, is characterized by an inefficient response to insulin by muscles, fat, and liver cells, inhibiting the easy absorption of glucose from the blood. This condition has ties to an unhealthy lifestyle, over-consumption of sugar, and genetic factors. A rise in diabetes and liver complications has led to an increased application of the concept of insulin resistance, which is managed with non-alcoholic steatohepatitis treatment. To illustrate, the International Diabetes Federation, a global diabetes group based in Belgium, reports that 537 million individuals, aged between 20 and 79, are affected by diabetes, representing one in every ten people. It predicts a rise to 643 million by 2030 and 783 million by 2045. In addition, a report by the Office for Health Improvement and Disparities, a department of the UK government, reveals that liver disease’s premature death rate rose 3.7% to 10,501 in 2021. Of these deaths, 5,686 were due to alcohol-related liver disease in England, with non-alcoholic fatty liver disease accounting for 320 premature deaths. Consequently, a rise in insulin resistance prevalence stemming from various liver and diabetes ailments will stimulate the non-alcoholic steatohepatitis treatment market.
Which Segments Are Important in the Non-Alcoholic Steatohepatitis Treatment Market Landscape?
The non-alcoholic steatohepatitis treatment market covered in this report is segmented –
1) By Drug Type: Vitamin E And Pioglitazone, Ocaliva, Elafibranor, Selonsertib And cenicriviroc, Obeticholic Acid, Other Drugs Types
2) By Test Type: Blood Tests, Liver Biopsy, Imaging Procedures
3) By End User: Hospital Pharmacies, Retail And Specialty Pharmacies, Other End Users
What Are the Latest Trends Impacting the Non-Alcoholic Steatohepatitis Treatment Market?
A significant trend emerging in the non-alcoholic steatohepatitis (NASH) treatment market is the progression in the creation of NASH medications. Numerous firms are directing their efforts towards the creation of breakthrough medicines for liver ailments, aiming to lessen the adverse effects of these drugs. For instance, Pfizer Inc., an established pharmaceutical and biotech firm from America, was awarded a fast-track designation by the U.S Food and Drug Administration (FDA) in May 2022. This fast-track status is designed to expedite the development of its NASH medication, specifically ervogastat and clesacostat. Fast Track is a mechanism meant to promote Pfizer’s experimental combination therapy for NASH with liver fibrosis treatment, named ervogastat (PF-06865571, a diacylglycerol O-acyltransferase 2 inhibitor, or DGAT2i) and clesacostat (PF-05221304, an acetyl-CoA carboxylase inhibitor, or ACCi).
Order Now for Fast Delivery of Your Non-Alcoholic Steatohepatitis Treatment Market Report!
What Regions Are Dominating the Non-Alcoholic Steatohepatitis Treatment Market Growth?
North America was the largest region in the non-alcoholic steatohepatitis treatment market share in 2023. The regions covered in the non-alcoholic steatohepatitis treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The Non-Alcoholic Steatohepatitis Treatment Global Market Report 2024 offers a comprehensive overview of the audio equipment market, covering historical data from 2010 to 2021 and providing a ten-year forecast from 2023 to 2032. This report examines the size of the non-alcoholic steatohepatitis treatment market, its market share, and analyzes key competitors along with their market positions.
The Table Of Content For The Non-Alcoholic Steatohepatitis Treatment Market Include
1. Non-Alcoholic Steatohepatitis Treatment Market Executive Summary
2. Non-Alcoholic Steatohepatitis Treatment Market Segments
3. Non-Alcoholic Steatohepatitis Treatment Market Size And Template Market Growth Rate
4. Key Non-Alcoholic Steatohepatitis Treatment Market Trends
5. Major Non-Alcoholic Steatohepatitis Treatment Market Drivers
……
25. Key Mergers And Acquisitions In The Non-Alcoholic Steatohepatitis Treatment Market
26. Top Non-Alcoholic Steatohepatitis Treatment Companies
27. Non-Alcoholic Steatohepatitis Treatment Market Opportunities And Strategies
28. Non-Alcoholic Steatohepatitis Treatment Market, Conclusions And Recommendations
29. Appendix
Discover Related Reports by The Business Research Company:
Panel Filters Global Market Report 2024
https://www.thebusinessresearchcompany.com/sample_request?id=7760&type=smp
Air Compressor Filter and Compressed Air Dryer Global Market Report 2024
Industrial Filtration Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/industrial-filtration-global-market-report
Learn More About The Business Research Company
The Business Research Company has published over 15000+ reports in 27 industries, spanning 60+ geographies. The reports draw on 1,500,000 datasets, extensive secondary research, and exclusive insights from interviews with industry leaders.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
